MedTrace Logo

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

NCT04679597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 161

Last updated 2024-10-17

No results posted yet for this study

Summary

In a retrospective study, the investigators will compare patients with locally advanced rectal cancer with high risk factors for failure who were treated with standard therapy or with total neoadjuvant therapy.

Conditions

Interventions

DRUG

Capecitabine

comparison of two treatments

Sponsors & Collaborators

  • Institute of Oncology Ljubljana

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679597 on ClinicalTrials.gov